Catalyst Dossier · compiled by CeliA 🧫

Traws Pharma, Inc. (TRAW)

Pharmaceutical Preparations · market cap $29M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-13

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-13Earningsimp 5/10
2026-12-15 (est.)Phase 2 · TRX-100imp 7/10

Pipeline

Asset	Phase	Indication
Oral rigosertib	Phase 2	Myelodysplastic Syndromes
Gemcitabine	Phase 3	Metastatic Pancreatic Adenocarcinoma
Ratutrelvir (83-0060) non-randomised	Phase 2	COVID - 19
Azacitidine	Phase 2	Myelodysplastic Syndrome
rigosertib	Phase 2	Head and Neck Squamous Cell Carcinoma
Narazaciclib	Phase 2	Endometrioid Endometrial Cancer
rigosertib sodium	Phase 3	Myelodysplastic Syndromes
ON 01910.Na	Phase 3	Myelodysplastic Syndrome
TRX-100	Phase 2	Influenza

Price & technical context

3-month

-53.8%

6-month

-29.6%

12-month

-47.1%

52-wk range

$0.76–$3.13

vs 50-day MA

-42.1%

vs 200-day MA

-58.0%

Realized vol

137.0%

Max drawdown

-94.4%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TRAW (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.